CD160 explained

CD160 antigen is a protein that in humans is encoded by the CD160 gene.^{[1] [2] [3]}

CD160 is a 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.^[4]

Clinical significance

CD160 is a ligand for HVEM, and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti- PD-1 antibodies.^[5] CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.^[6]

Related gene problems

• TAR syndrome^[7]
• 1q21.1 deletion syndrome
• 1q21.1 duplication syndrome

See also

• Cluster of differentiation

Further reading

• Bensussan A, Gluckman E, el Marsafy S . BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. . Proc. Natl. Acad. Sci. U.S.A. . 91 . 19 . 9136–40 . 1994 . 8090781 . 10.1073/pnas.91.19.9136 . 44762 . 1994PNAS...91.9136B . etal. free .
• Nikolova M, Marie-Cardine A, Boumsell L, Bensussan A . BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. . Int. Immunol. . 14 . 5 . 445–51 . 2002 . 11978774 . 10.1093/intimm/14.5.445 . free .
• Strausberg RL, Feingold EA, Grouse LH . Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. . Proc. Natl. Acad. Sci. U.S.A. . 99 . 26 . 16899–903 . 2003 . 12477932 . 10.1073/pnas.242603899 . 139241 . 2002PNAS...9916899M . etal. free .
• Tanaka J, Toubai T, Tsutsumi Y . Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. . Blood . 104 . 3 . 768–74 . 2004 . 15073036 . 10.1182/blood-2003-11-3870 . etal. free .
• Gerhard DS, Wagner L, Feingold EA . The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). . Genome Res. . 14 . 10B . 2121–7 . 2004 . 15489334 . 10.1101/gr.2596504 . 528928 . etal.
• Barakonyi A, Rabot M, Marie-Cardine A . Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. . J. Immunol. . 173 . 9 . 5349–54 . 2004 . 15494480 . 10.4049/jimmunol.173.9.5349. etal. free .
• Abecassis S, Giustiniani J, Meyer N . Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. . J. Invest. Dermatol. . 127 . 5 . 1161–6 . 2007 . 17218942 . 10.1038/sj.jid.5700680 . etal. free .
• Giustiniani J, Marie-Cardine A, Bensussan A . A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity. . J. Immunol. . 178 . 3 . 1293–300 . 2007 . 17237375 . 10.4049/jimmunol.178.3.1293. free .

Notes and References

1. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, Patel AT, Robertson MJ, Nadler LM, Freeman GJ . Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes . J Immunol . 161 . 6 . 2780–90 . Oct 1998 . 10.4049/jimmunol.161.6.2780 . 9743336 . 25536877 . free .
2. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, Bolton W, Ogg G, Boumsell L, Bensussan A . Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells . J Immunol . 162 . 3 . 1223–6 . Apr 1999 . 10.4049/jimmunol.162.3.1223 . 9973372 . 23169904 . free .
3. Web site: Entrez Gene: CD160 CD160 molecule.
4. Web site: Entrez Gene: CD160 CD160 molecule.
5. Stecher. Carmen. Battin. Claire. Leitner. Judith. Zettl. Markus. Grabmeier-Pfistershammer. Katharina. H?ller. Christoph. Zlabinger. Gerhard J.. Steinberger. Peter. PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Frontiers in Immunology. 22 May 2017. 8. 572. 10.3389/fimmu.2017.00572. 5439058. 28588576. free.
6. Chabot. Sophie. Jabrane-Ferrat. Nabila. Bigot. Karine. Tabiasco. Julie. Provost. Alexandra. Golzio. Muriel. Noman. Muhammad Zaeem. Giustiniani. J?r?me. Bellard. Elisabeth. Brayer. St?phanie. Aguerre-Girr. Maryse. Meggetto. Fabienne. Giuriato. Sylvie. Malecaze. Fran?ois. Galiacy. St?phane. Ja?s. Jean-Philippe. Chose. Olivier. Kadouche. Jean. Chouaib. Salem. Teissi?. Justin. Abitbol. Marc. Bensussan. Armand. Le Bouteiller. Philippe. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. The Journal of Experimental Medicine. 9 May 2011. 208. 5. 973–986. 10.1084/jem.20100810. 3092350. 21482699.
7. Klopocki E, Schulze H, Strauss G . Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome . Am. J. Hum. Genet. . 80 . 2 . 232–40 . February 2007 . 17236129 . 1785342 . 10.1086/510919 . etal.